Allergic Rhinitis (Seasonal & Perennial) affects 10-30% of the global population and approximately 60 million people in the United States, making it one of the largest chronic inflammatory disease markets worldwide. The condition is characterized by rhinorrhea, nasal congestion, itching, and sneezing, which significantly impact quality of life and are commonly assessed using the Total Nasal Symptom Score (TNSS). The U.S. allergic rhinitis market is estimated at approximately US$3.5 billion and is projected to approach US$5 billion. ALDP001 is a differentiated antihistamine nasal therapy designed to provide broader control of allergic inflammation through modulation of H₁, H₂, and H₄ histamine pathways. It is intended as a first-line treatment option for a large allergic rhinitis patient population, offering comprehensive symptom relief and improved disease management.

Allergic Rhinitis (Seasonal & Perennial) affects 10-30% of the global population and approximately 60 million people in the United States, making it one of the largest chronic inflammatory disease markets worldwide. The condition is characterized by rhinorrhea, nasal congestion, itching, and sneezing, which significantly impact quality of life and are commonly assessed using the Total Nasal Symptom Score (TNSS). The U.S. allergic rhinitis market is estimated at approximately US$3.5 billion and is projected to approach US$5 billion. ALDP021 is a next-generation combination therapy comprising ALDP001 and a topical corticosteroid, targeting the fastest-growing segment of the allergic rhinitis market. The broader nasal spray market exceeds US$10 billion, providing a significant commercial opportunity. Designed for patients with moderate-to-severe allergic rhinitis, ALDP021 aims to deliver enhanced symptom control beyond antihistamine monotherapy by combining anti-allergic and anti-inflammatory mechanisms. The therapy may also help reduce the risk of chronic rhinitis progression and related complications, including nasal polyps, while addressing unmet needs in patients requiring more intensive treatment.

Colorectal Cancer (CRC) is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related death, with approximately 2 million new cases and 920,000 deaths annually. The United States remains one of the largest CRC markets, with over 150,000 new cases diagnosed each year, while incidence continues to rise in younger adults. The global CRC therapeutics market is estimated at US$12-15 billion and is projected to exceed US$20 billion, driven by increasing disease burden, adoption of targeted therapies, and growing demand for more effective treatments in advanced and metastatic disease. Since, many patients eventually experience disease progression due to acquired resistance mechanisms and emerging molecular alterations, resulting in limited progression-free survival (PFS) and reduced overall survival. ALK-201, with its first-in-class mechanism of action, is a differentiated therapeutic candidate designed to inhibit tumor cell proliferation while simultaneously targeting angiogenesis through precise signaling pathways implicated in colorectal cancer progression, therapeutic resistance, and disease recurrence.

Lower-Extremity Vascular Ischemia & Diabetic Foot Ulcers (DFU) represent a significant and growing global healthcare challenge. Peripheral arterial disease (PAD), a major cause of lower-extremity ischemia, affects approximately 236 million people worldwide, while an estimated 18.6 million patients develop diabetic foot ulcers annually, including approximately 1.6 million patients in the United States. Patients with DFUs face high risks of poor wound healing, amputation, and mortality, highlighting a substantial unmet medical need. The market opportunity is significant, with the global PAD market valued at approximately US$7-8 billion and projected to exceed US$11-15 billion over the next decade, driven by rising diabetes prevalence, aging populations, and increasing demand for limb-preserving therapies. ALK-202, a regenerative therapy, is being developed as a differentiated therapeutic approach that targets the underlying vascular ischemia driving diabetic foot ulcer development and progression, with the potential to improve tissue perfusion, promote tissue regeneration and repair, enhance limb salvage, and reduce amputation risk.

Diabetic Peripheral Neuropathy (DPN) is one of the most common complications of diabetes, affecting an estimated 30-50% of diabetic patients globally and causing chronic pain, numbness, tingling, and sensory loss that significantly impair quality of life and increase the risk of foot ulcers and amputations. With diabetes affecting more than 500 million adults worldwide, the burden of DPN continues to rise, creating a substantial unmet medical need. The global diabetic neuropathy treatment market is valued at over US$4 billion and is projected to grow steadily as the prevalence of diabetes increases and demand for more effective therapies expands. ALK203 is a Phase 2 investigational therapy designed to address the underlying disease biology of DPN by targeting key drivers of neuropathic pain and nerve dysfunction. With the potential to improve symptom control and patient outcomes beyond currently available treatment options, ALK203 is positioned to address a large and growing patient population in a market seeking safer and more effective long-term therapies.